{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T01:49:23Z","timestamp":1783216163660,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Provincial Health Commission of China","award":["Z2019053"],"award-info":[{"award-number":["Z2019053"]}]},{"name":"Natural Science Foundation of the Jiangsu Higher Education Institutions of China","award":["21KJB360013"],"award-info":[{"award-number":["21KJB360013"]}]},{"name":"Natural Science Foundation of the Jiangsu Higher Education Institutions of China","award":["18KJB320004"],"award-info":[{"award-number":["18KJB320004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most classic treatment recommended in the current chronic obstructive pulmonary disease (COPD) guidelines is glucocorticoid and \u03b22 receptor agonist combination, such as salmeterol xinafoate and fluticasone propionate (Sal\/Flu), causing many adverse reactions due to hormones. Magnesium isoglycyrrhizinate (MgIG) is an anti-inflammatory glycyrrhizic acid preparation for treating chronic inflammation, contributing to its structure is similar to steroidal anti-inflammatory drugs. In this study, we successfully established COPD rat model by endotracheal-atomized lipopolysaccharide exposure and cigarette smoke induction, as characterized by lung function decline. We discovered that salmeterol xinafoate\/MgIG combination could alleviated lung inflammation infiltration, airway wall thickness (AWT) and the secretion of bronchial mucin MUC5AC of COPD rats more than salmeterol xinafoate, MgIG, or salmeterol xinafoate and fluticasone propionate treatment did, as well as reduced inflammatory cells (white blood cells, neutrophils and lymphocytes) accumulation in bronchoalveolar lavage fluid and decreased TNF-\u03b1, IL-6 and IL-1\u03b2 production in the serum of COPD rats. Finally, we found that Moreover, the mechanism involved might be related to the suppression of JAK\/STAT signaling pathway. Overall, our studies suggested that MgIG might be a potential alternative adjuvant drug for fluticasone propionate for the clinical treatment of patients with COPD.<\/jats:p>","DOI":"10.1038\/s41598-022-16775-2","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T15:04:30Z","timestamp":1658243070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Ye","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongchong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"16775_CR1","doi-asserted-by":"publisher","first-page":"105938","DOI":"10.1016\/j.rmed.2020.105938","volume":"166","author":"CF Vogelmeier","year":"2020","unstructured":"Vogelmeier, C. F. et al. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir. Med. 166, 105938. https:\/\/doi.org\/10.1016\/j.rmed.2020.105938 (2020).","journal-title":"Respir. Med."},{"key":"16775_CR2","doi-asserted-by":"publisher","first-page":"e0487","DOI":"10.1097\/MD.0000000000010487","volume":"97","author":"SK Gadre","year":"2018","unstructured":"Gadre, S. K. et al. Acute respiratory failure requiring mechanical ventilation in severe chronic obstructive pulmonary disease (COPD). Medicine (Baltimore) 97, e0487. https:\/\/doi.org\/10.1097\/MD.0000000000010487 (2018).","journal-title":"Medicine (Baltimore)"},{"key":"16775_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.17116\/terarkh201688332-35","volume":"88","author":"IZ Aksenova","year":"2016","unstructured":"Aksenova, I. Z. & Burduli, N. M. Pathogenetic effects of low-intensity laser therapy for chronic obstructive pulmonary disease. Ter Arkh. 88, 32\u201335. https:\/\/doi.org\/10.17116\/terarkh201688332-35 (2016).","journal-title":"Ter Arkh."},{"key":"16775_CR4","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2147\/COPD.S161555.eCollection2018","volume":"13","author":"B Zhu","year":"2018","unstructured":"Zhu, B., Wang, Y., Ming, J., Chen, W. & Zhang, L. Disease burden of COPD in China: A systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 1353\u20131364. https:\/\/doi.org\/10.2147\/COPD.S161555.eCollection2018 (2018).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"16775_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1164\/rccm.201512-2340ED","volume":"193","author":"H Watz","year":"2016","unstructured":"Watz, H. Chronic obstructive pulmonary disease: When pulmonologists do something good for the heart. Am. J. Respir. Crit. Care Med. 193, 703\u2013704. https:\/\/doi.org\/10.1164\/rccm.201512-2340ED (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"16775_CR6","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha, J. A. et al. FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 374, 2222\u20132234. https:\/\/doi.org\/10.1056\/NEJMoa1516385 (2016) ((epub 2016 May 15)).","journal-title":"N. Engl. J. Med."},{"key":"16775_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","volume":"20","author":"F Maltais","year":"2019","unstructured":"Maltais, F. et al. Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: The EMAX randomised trial. Respir. Res. 20, 238. https:\/\/doi.org\/10.1186\/s12931-019-1193-9 (2019).","journal-title":"Respir. Res."},{"key":"16775_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1586\/17476348.1.1.25","volume":"1","author":"KF Chung","year":"2006","unstructured":"Chung, K. F. Salmeterol\/fluticasone combination in the treatment of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 1, 235\u2013242. https:\/\/doi.org\/10.1586\/17476348.1.1.25 (2006).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"16775_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0192-0561(96)00008-2","volume":"18","author":"IC Mohede","year":"1996","unstructured":"Mohede, I. C., Van Ark, I., Brons, F. M., Van Oosterhout, A. J. & Nijkamp, F. P. salmeterol inhibits interferon-gamma and interleukin-4 production by human peripheral blood mononuclear cells. Int. J. Immunopharmacol. 18, 193\u2013201. https:\/\/doi.org\/10.1016\/0192-0561(96)00008-2 (1996).","journal-title":"Int. J. Immunopharmacol."},{"key":"16775_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.18553\/jmcp.2016.22.4.316","volume":"22","author":"E Yip","year":"2016","unstructured":"Yip, E., Karimi, S. & Pien, L. T. Evaluation of a therapeutic interchange from fluticasone\/salmeterol to mometasone\/formoterol in patients with chronic obstructive pulmonary disease. J. Manag. Care Spec. Pharm. 22, 316\u2013323. https:\/\/doi.org\/10.18553\/jmcp.2016.22.4.316 (2016).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"16775_CR11","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3892\/etm.2017.5562","volume":"15","author":"Z Wang","year":"2018","unstructured":"Wang, Z., Wang, C. & Yang, X. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. Exp. Ther. Med. 15, 1538\u20131545. https:\/\/doi.org\/10.3892\/etm.2017.5562 (2018).","journal-title":"Exp. Ther. Med."},{"key":"16775_CR12","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.rmed.2007.07.014","volume":"101","author":"J Bousquet","year":"2007","unstructured":"Bousquet, J. et al. Budesonide\/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol\/fluticasone. Respir. Med. 101, 2437\u20132446. https:\/\/doi.org\/10.1016\/j.rmed.2007.07.014 (2007).","journal-title":"Respir. Med."},{"key":"16775_CR13","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3892\/ijmm.2018.3787","volume":"42","author":"X Zou","year":"2018","unstructured":"Zou, X. et al. Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin-induced model of liver injury. Int. J. Mol. Med. 42, 2020\u20132030. https:\/\/doi.org\/10.3892\/ijmm.2018.3787 (2018).","journal-title":"Int. J. Mol. Med."},{"key":"16775_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jep.2013.12.015","volume":"18","author":"ZW Xiao","year":"2014","unstructured":"Xiao, Z. W., Zhang, W., Ma, L. & Qiu, Z. W. Therapeutic effect of magnesium isoglycyrrhizinate in rats on lung injury induced by paraquat poisoning. Eur. Rev. Med. Pharmacol. Sci. 18, 311\u2013320. https:\/\/doi.org\/10.1016\/j.jep.2013.12.015 (2014).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"16775_CR15","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.21037\/apm-20-1971","volume":"10","author":"C Tang","year":"2021","unstructured":"Tang, C., Ding, H., Sun, Y., Han, Z. & Kong, L. A narrative review of COVID-19: Magnesium isoglycyrrhizinate as a potential adjuvant treatment. Ann. Palliat. Med. 10, 4777\u20134798. https:\/\/doi.org\/10.21037\/apm-20-1971 (2021).","journal-title":"Ann. Palliat. Med."},{"key":"16775_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12890-021-01745-7","volume":"21","author":"Y Yang","year":"2021","unstructured":"Yang, Y., Huang, L., Tian, C. & Qian, B. Magnesium isoglycyrrhizinate inhibits airway inflammation in\u00a0rats with\u00a0chronic obstructive pulmonary disease. BMC Pulmon. Med. 21, 371. https:\/\/doi.org\/10.1186\/s12890-021-01745-7 (2021).","journal-title":"BMC Pulmon. Med."},{"key":"16775_CR17","doi-asserted-by":"publisher","first-page":"9125","DOI":"10.18632\/aging.103180","volume":"12","author":"K Zhao","year":"2020","unstructured":"Zhao, K. et al. Cigarette smoke-induced lung inflammation in COPD mediated via CCR1\/JAK\/STAT \/NF-\u03baB pathway. Aging (Albany) 12, 9125\u20139138. https:\/\/doi.org\/10.18632\/aging.103180 (2020).","journal-title":"Aging (Albany)"},{"key":"16775_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1183\/09031936.00228414","volume":"46","author":"L Yew-Booth","year":"2015","unstructured":"Yew-Booth, L. et al. JAK-STAT pathway activation in COPD. Eur. Respir. J. 46, 843\u2013845. https:\/\/doi.org\/10.1183\/09031936.00228414 (2015).","journal-title":"Eur. Respir. J."},{"key":"16775_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000481558","volume":"43","author":"C Wang","year":"2017","unstructured":"Wang, C., Ding, H., Tang, X., Li, Z. & Gan, L. Effect of Liuweibuqi capsules in pulmonary alveolar epithelial cells and COPD through JAK\/STAT pathway. Cell Physiol. Biochem. 43, 743\u2013756. https:\/\/doi.org\/10.1159\/000481558 (2017).","journal-title":"Cell Physiol. Biochem."},{"key":"16775_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12931-014-0156-4","volume":"15","author":"Y Qi","year":"2014","unstructured":"Qi, Y. et al. Inhibition of AMPK expression in skeletal muscle by systemic inflammation in COPD rats. Respir. Res. 15, 156. https:\/\/doi.org\/10.1186\/s12931-014-0156-4 (2014).","journal-title":"Respir. Res."},{"key":"16775_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08923973.2022.2055567","volume":"29","author":"Y Yang","year":"2022","unstructured":"Yang, Y., Huang, L., Tian, C. & Qian, B. Magnesium isoglycyrrhizinate alleviate airway inflammatory responses in ovalbumin-induced mouse model of allergic asthma. Immunopharmacol. Immunotoxicol. 29, 1\u20139. https:\/\/doi.org\/10.1080\/08923973.2022.2055567 (2022).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"16775_CR22","unstructured":"World Health Organization. Chronic Obstructive Pulmonary Disease (COPD). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd). Accessed 20 May 2022 (2019)."},{"key":"16775_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley, P. M. et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775\u2013789. https:\/\/doi.org\/10.1056\/NEJMoa063070 (2007).","journal-title":"N. Engl. J. Med."},{"key":"16775_CR24","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1378\/chest.123.6.1817","volume":"123","author":"GT Ferguson","year":"2003","unstructured":"Ferguson, G. T., Funck-Brentano, C., Fischer, T., Darken, P. & Reisner, C. Cardiovascular safety of salmeterol in COPD. Chest 123, 1817\u20131824. https:\/\/doi.org\/10.1378\/chest.123.6.1817 (2003).","journal-title":"Chest"},{"key":"16775_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s0192-0561(99)00030-2","volume":"21","author":"EJ de Waal","year":"1999","unstructured":"de Waal, E. J., de Jong, W. H., van der Stappen, A. J., Verlaan, B. & van Loveren, H. Effects of salmeterol on host resistance to Trichinella spiralis in rats. Int. J. Immunopharmacol. 21, 523\u2013529. https:\/\/doi.org\/10.1016\/s0192-0561(99)00030-2 (1999).","journal-title":"Int. J. Immunopharmacol."},{"key":"16775_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/bcr.09.2009.2264","volume":"2010","author":"A Myers","year":"2010","unstructured":"Myers, A. & Godden, C. Peripheral oedema as a side-effect of fluticasone. BMJ Case Rep. 2010, 264. https:\/\/doi.org\/10.1136\/bcr.09.2009.2264 (2010).","journal-title":"BMJ Case Rep."},{"key":"16775_CR27","doi-asserted-by":"publisher","first-page":"33252","DOI":"10.18632\/oncotarget.16629","volume":"8","author":"W Jiang","year":"2017","unstructured":"Jiang, W. et al. Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury. Oncotarget 8, 33252\u201333264. https:\/\/doi.org\/10.18632\/oncotarget.16629 (2017).","journal-title":"Oncotarget"},{"key":"16775_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3892\/mmr.2021.12077","volume":"23","author":"M Liu","year":"2021","unstructured":"Liu, M. et al. Exploration of the hepatoprotective effect and mechanism of magnesium isoglycyrrhizinate in mice with arsenic trioxide-induced acute liver injury. Mol. Med. Rep. 23, 438. https:\/\/doi.org\/10.3892\/mmr.2021.12077 (2021).","journal-title":"Mol. Med. Rep."},{"key":"16775_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1165\/rcmb.2009-0220TR","volume":"41","author":"PJ Barnes","year":"2009","unstructured":"Barnes, P. J. The cytokine network in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 41, 631\u2013638. https:\/\/doi.org\/10.1165\/rcmb.2009-0220TR (2009).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"16775_CR30","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.biopha.2018.09.166","volume":"108","author":"S Uniyal","year":"2018","unstructured":"Uniyal, S., Dhasmana, A., Tyagi, A. & Muyal, J. P. ATRA reduces inflammation and improves alveolar epithelium regeneration in emphysematous rat lung. Biomed. Pharmacother. 108, 1435\u20131450. https:\/\/doi.org\/10.1016\/j.biopha.2018.09.166 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"16775_CR31","doi-asserted-by":"publisher","first-page":"e85243","DOI":"10.1371\/journal.pone.0085243","volume":"9","author":"T Victoni","year":"2014","unstructured":"Victoni, T. et al. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK\/STAT and ERK1\/2 inhibition in airway epithelial cells. PLoS ONE 9, e85243. https:\/\/doi.org\/10.1371\/journal.pone.0085243 (2014).","journal-title":"PLoS ONE"},{"key":"16775_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","volume":"19","author":"J Milara","year":"2018","unstructured":"Milara, J. et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir. Res. 19, 24. https:\/\/doi.org\/10.1186\/s12931-018-0728-9 (2018).","journal-title":"Respir. Res."},{"key":"16775_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12872-020-01391-7","volume":"20","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Inhibition of JAK2\/STAT3\/SOCS3 signaling attenuates atherosclerosis in rabbit. BMC Cardiovasc. Disord. 20, 133. https:\/\/doi.org\/10.1186\/s12872-020-01391-7 (2020).","journal-title":"BMC Cardiovasc. Disord."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16775-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16775-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:45:51Z","timestamp":1669351551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16775-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16775"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16775-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"28 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12334"}}